Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period
SAN FRANCISCOand SUZHOU,China,Oct.7,2020 -- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical company that develops,manufactures and commercializes high-quality medicines for the treatment of oncology,metabolic,autoimmune and other major diseases,announcesthe expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,as amended (the "HSR Act"),in connection with the previously announced global expansion collaboration agreement between Innovent and Eli Lilly and Company ("Lilly") for TYVYT® (sintilimab injection). The agreement now becomes effective immediately. This milestone triggers the $200 million upfront payment milestone referenced in the parties' August 18,2020 press release.
About TYVYT® (Sintilimab Injection)
TYVYT® (sintilimab injection),an innovative drug with global quality standards jointly developed in China by Innovent and Lilly,has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy,and included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT® (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List (NRDL),in November 2019. In April 2020,the NMPA accepted the sNDA for TYVYT® (sintilimab injection) in combination with ALIMTA® (pemetrexed) and platinum chemotherapy as first-line therapy for the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). In May 2020,TYVYT® (sintilimab injection) monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma. In August 2020,the NMPA accepted the sNDA for TYVYT® (sintilimab injection) in combination with GEMZAR® (gemcitabine for injection) and platinum chemotherapy as first-line therapy in squamous NSCLC. In September 2020,TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab injection) as a first-line treatment in advanced hepatocellular carcinoma met the predefined primary endpoints in an interim analysis of the Phase 3 ORIENT-32 study.
TYVYT® (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody,which binds to PD-1 molecules on the surface of T-cells,blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies for TYVYT® (sintilimab injection) to evaluate its safety and efficacy in a wide variety of cancer indications,including more than 10 registrational or pivotal clinical trials. Meanwhile,Innovent is conducting clinical research studies on TYVYT® (sintilimab injection) worldwide.
About Innovent
Inspired by the spirit of "Start with Integrity,Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011,Innovent is committed to developing,manufacturing and commercializing high-quality innovative medicines for the treatment of cancer,autoimmune and other major diseases. On October 31,2018,Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception,Innovent has developed a fully integrated multi-functional platform which includes R&D,CMC (Chemistry,Manufacturing,and Controls),clinical development and commercialization capabilities. Leveraging the platform,the company has built a robust pipeline of 23 valuable assets in the fields of cancer,autoimmune diseases and other major therapeutic areas,with three products,TYVYT® (sintilimab injection),BYVASDA® (bevacizumab injection) and SULINNO® (adalimumab injection),on market,one asset under NDA review with priority review status,four assets in Phase 3 or pivotal clinical trials,and additional 15 molecules in or close to clinical trials. TYVYT® (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.
Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company,Adimab,Incyte,Alector,MD Anderson Cancer Center,Hanmi and other international partners. For more information,please visit: www.innoventbio.com.
About Innovent's strategic collaboration with Eli Lilly and Company
Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 – a groundbreaking partnership between a Chinese pharmaceuticalcompany and a multinational pharmaceutical company. Under the agreement,Innovent and Lilly are co-developing and commercializing oncology medicines,including TYVYT®(sintilimab injection) in China. In October 2015,the two companies announced the extension of their existing collaboration to includeco-development of three additionaloncology antibodies targeting oncology indications. In August 2019,Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. Its collaboration with Lilly indicates that Innovent has established a comprehensive level of cooperation between China's innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D,CMC,clinical development and commercialization. In August 2020，Lilly and Innovent announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection),and Lilly will obtain an exclusive license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection) is not an approved product in the United States.
SULINNO® (adalimumab biosimilar injection) is not an approved product in the United States.
TYVYT® (sintilimab injection,Innovent)
BYVASDA®(bevacizumab biosimilar injection,Innovent)
SULINNO® (adalimumab biosimilar injection,Innovent)
ALIMTA®and GEMZAR®are trademarks owned by or licensed to Eli Lilly and Company,its subsidiaries,or affiliates.
